NUDT1 and glioblastoma: This notion is further strengthened by the fact that glioblastoma cells deficient in MTH1 were shown to display a higher sensitivity to Temozolomide compared to MTH1 proficient cells, most likely through different abilities to remove formed O6-methyl-dGTP.